Cardiac sarcoidosis and giant cell myocarditis after COVID‐19 infection. (22nd August 2022)

• Record Type: Journal Article
• Authors: Bollano, Entela; Polte, Christian Lars; Mäyränpää, Mikko I.; Oldfors, Anders; Bergh, Niklas; Lehtonen, Jukka; Kandolin, Riina
• Is Part Of: ESC heart failure. Volume 9:Number 6(2022)
• Page Start: 4298
• Page End: 4303
• Publication Date: 2022-08-22
• Subjects: Cardiac sarcoidosis -- Giant cell myocarditis -- COVID‐19 -- Heart failure; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.14088
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1–8 months after mild COVID‐19. All patients received immunosuppressive therapy and improved gradually within the following months. The possible temporal association between the CS/GCM and COVID‐19 infection might suggest that COVID‐19 could be a trigger for granulomatous myocarditis.